BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

Barry Greene, who has worked with CEO John Maraganore to build Alnylam for the past 17 years, will depart the RNAi company as president at the end of the quarter. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) said...
BioCentury | Jul 30, 2020
Finance

July 28 Quick Takes: Venture round reveals for Omega, Praxis, HaiHe; plus trio of NASDAQ IPO filings, Atsena’s debut, La Jolla-Tetraphase

Omega reveals venture tally Omega Therapeutics Inc. announced it has raised $85 million since its 2016 launch by Flagship Pioneering to support development of therapies targeting chromatin structures. The funding includes a series A round...
BioCentury | May 30, 2020
Product Development

May 29 ASCO Quick Takes: Investors sour on Arvinas’ targeted degraders; plus MacroGenics, Karyopharm, Blueprint

Targeted degrader company Arvinas takes hit on updated proof of concept data Arvinas Inc. (NASDAQ:ARVN) shed nearly $500 million in market cap Friday after updated Phase I/II data showed no new responses among 12 additional...
BioCentury | May 1, 2020
Regulation

China's proposed annual NRDL revisions could increase pricing pressure

China's proposed guidelines regarding the annual revision of its National Drug Reimbursement List could increase pricing pressure for all included drugs. Draft opinions released by China’s National Healthcare Security Administration (NHSA) Wednesday proposed extending price...
BioCentury | Mar 26, 2020
Regulation

China’s NMPA suspends Abraxane imports after U.S. inspection

China’s suspension of the importation and sale of Celgene’s Abraxane by BeiGene following an inspection at a U.S. manufacturing site demonstrates how far the country has come in its drive to ensure safety of drugs,...
BioCentury | Mar 3, 2020
Product Development

Following Phase III readout, Karyopharm seeks approval of Xpovio for second-line MM

Karyopharm gained $11.38 (70%) to $27.72 on Monday, adding about $746 million in market value, after announcing that Xpovio selinexor met the primary endpoint of improving PFS in the confirmatory Phase III BOSTON trial to...
BioCentury | Dec 31, 2019
Company News

Dec. 31 Company Quick Takes: A first for BeiGene; plus MorphoSys, Junshi-CSPC, Acceleron-Fulcrum and Solasia-EditForce

First-ever China approval for homegrown BeiGene drug China’s National Medical Products Administration approved anti-PD-1 mAb tislelizumab from BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) to treat classical Hodgkin lymphoma in a third-line setting. The approval is the first...
BioCentury | Dec 18, 2019

The proteasome-regulating kinase DYRK2 as a target in breast cancer and multiple myeloma

DISEASE CATEGORY: Cancer INDICATION: Breast cancer; multiple myeloma (MM) Inhibiting the proteasome-regulating kinase DYRK2 could treat breast cancer and MM. In patients with triple-negative breast cancer (TNBC) or MM, DYRK2 expression and protein levels were...
BioCentury | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

EMA's CHMP issued a positive opinion for Novartis’ Beovu brolucizumab in its December roundup of opinions, none of which were negative. The agency backed an MAA from Novartis AG (NYSE:NVS; SIX:NOVN) for Beovu to treat...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

Grace Science is targeting the root of a recently discovered genetic disorder for not just the ultra-rare condition but also for common diseases including cancer. Grace Science LLC’s origins stem from the diagnosis of co-founder...
Items per page:
1 - 10 of 819